Amarin Corporation (AMRN, Financial) experienced a significant stock price increase of 5.08%. The stock is currently priced at $0.520 per share, with a trading volume of 1.44 million shares and a turnover rate of 0.35%. The stock's price fluctuation is 4.94%.
Recent financial reports reveal that Amarin achieved a revenue of $42.73 million, with a net loss of $25.39 million. The earnings per share (EPS) stand at -$0.06, and the gross profit is $15.68 million. The price-to-earnings (P/E) ratio is -5.13.
In terms of institutional ratings, out of three firms, 33% recommend holding the stock, while 67% suggest selling. No institutions have given a buy recommendation.
Within the pharmaceutical industry, where Amarin operates, the overall sector saw a slight decline of 0.18%. Noteworthy performers in the industry include Procaps Group, S.A., Flora Growth Corp., and Avadel Pharmaceuticals Plc, which recorded notable gains. Other active stocks include Painreform Ltd., Sonoma Pharmaceuticals, Inc., and Canopy Growth Corporation, with respective turnover rates of 76.08%, 21.04%, and 4.47%. Stocks with significant price fluctuations include Procaps Group, S.A. (89.24%), Procaps Group S.A. C/Wts 29/09/2026 (To Pur Com) (62.68%), and Optinose, Inc. (24.66%).
Amarin Corporation is a biopharmaceutical company focusing on the commercialization and development of therapeutic drugs to enhance cardiovascular health and reduce cardiovascular risk. Its flagship product is Vascepa.
